These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7015425)

  • 41. [Bestatin treatment of patients with myelodysplastic syndromes].
    Uzuka Y; Saito Y
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):365-70. PubMed ID: 2930201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prospective randomized controlled study of bestatin in gastric cancer surgery].
    Yoshinaka K; Tanaka T; Takagami S; Saeki T; Nishiyama M; Toge T; Niimoto M; Hattori T
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):493-8. PubMed ID: 3126708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Initial results of the clinical use of the immunostimulant bestatin (3-amino-2-hydroxy-4-phenylbutyryl leucine) in patients with chronic polyarthritis].
    Meske S; Vogt P; Maly FE; Seitz M; Müller W
    Z Rheumatol; 1985; 44(5):231-6. PubMed ID: 4082790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Secondary microbial metabolites with potentials for antineoplastic actions: antineoplastic antibiotics and immunopotentiators].
    Umezawa H
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1071-86. PubMed ID: 6191672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of bestatin on immuno-suppressive acidic protein in patients with stomach cancer].
    Ishii T; Takeshita K; Sunagawa M; Habu H; Hoshi K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1585-90. PubMed ID: 6476836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunopotentiation in infectious disease, II. Effect of bestatin on experimental infection.
    Ormrod DJ; Clarke IA; Miller TE
    Chemioterapia; 1985 Aug; 4(4):324-8. PubMed ID: 3902258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Biological effect of bestatin against rat ascites hepatomas and enhancement of interferon production].
    Satoh H
    Jpn J Antibiot; 1984 Apr; 37(4):593-6. PubMed ID: 6206251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bestatin as adjuvant treatment in operated stage I and stage II non-small cell lung cancer. European Lung Cancer Study Group.
    Mouritzen C
    Acta Oncol; 1990; 29(6):817-20. PubMed ID: 2171596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
    Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
    Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Correction of immunodeficiency in aged mice by levamisole and bestatin administration.
    Bruley-Rosset M; Florentin I; Kiger N; Schulz JI; Mathé G
    Recent Results Cancer Res; 1980; 75():139-46. PubMed ID: 7232825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.
    Abe F; Schneider M; Black PL; Talmadge JE
    Cancer Immunol Immunother; 1989; 29(4):231-6. PubMed ID: 2752391
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
    Inoi K; Goto S; Nomura S; Isobe K; Nawa A; Okamoto T; Tomoda Y
    Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)].
    Akiya K; Negishi Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):1025-9. PubMed ID: 2410519
    [No Abstract]   [Full Text] [Related]  

  • 55. [Experimental and clinical studies of bestatin as an immunomodulator].
    Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin.
    Uchibayashi T; Kunimi K; Yamamoto H; Koshida K
    Int J Clin Pharmacol Ther; 1995 Aug; 33(8):465-8. PubMed ID: 8556228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Double-blind trial of bestatin in HIV-positive patients.
    Hørding M; Gøtzsche PC; Dalh Christensen L; Bygbjerg IC; Faber V
    Biomed Pharmacother; 1990; 44(9):475-8. PubMed ID: 2081275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A review of clinical studies of pepleomycin.
    Oka S
    Recent Results Cancer Res; 1980; 74():163-71. PubMed ID: 6160600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. From experimental to clinical attempts in immunorestoration with bestatin and zinc.
    Mathé G; Blazsek I; Canon C; Gil-Delgado M; Misset JL
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):241-52. PubMed ID: 3539499
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin.
    Chen X; Li N; Wang S; Wu N; Hong J; Jiao X; Krasna MJ; Beer DG; Yang CS
    J Natl Cancer Inst; 2003 Jul; 95(14):1053-61. PubMed ID: 12865451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.